These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 26244011)
1. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Kundranda MN; Niu J Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011 [TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157 [TBL] [Abstract][Full Text] [Related]
3. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875 [TBL] [Abstract][Full Text] [Related]
4. The winning formulation: the development of paclitaxel in pancreatic cancer. Ma WW; Hidalgo M Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602 [TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310 [TBL] [Abstract][Full Text] [Related]
8. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370 [TBL] [Abstract][Full Text] [Related]
9. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Guarneri V; Dieci MV; Conte P Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900 [TBL] [Abstract][Full Text] [Related]
10. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Vishnu P; Roy V Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612 [TBL] [Abstract][Full Text] [Related]
11. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Zong Y; Wu J; Shen K Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451 [TBL] [Abstract][Full Text] [Related]
12. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Kudlowitz D; Muggia F Expert Opin Drug Saf; 2014 Jun; 13(6):681-5. PubMed ID: 24749649 [No Abstract] [Full Text] [Related]
13. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation]. Lipp HP Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109 [TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Henderson IC; Bhatia V Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452 [TBL] [Abstract][Full Text] [Related]
15. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma. Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683 [TBL] [Abstract][Full Text] [Related]
17. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813 [TBL] [Abstract][Full Text] [Related]
18. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer. Hoy SM Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887 [TBL] [Abstract][Full Text] [Related]
19. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079 [TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]